Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
Definium Therapeutics (DFTX) will host a webcast on September 14, 2026, to discuss topline results from its Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder. The study enrolled 245 participants across 32 centers, with primary endpoints focused on changes in HAM-A and CGI-S scores. Definium Therapeutics is a Nasdaq-listed biopharmaceutical company developing psychiatric and neurological disorder treatments.
How this was made
The 30-second read
Why it matters
The webcast will be the first public disclosure of the trial’s topline efficacy and safety data, a catalyst that typically drives significant price movement in biotech stocks.
Market read
The upcoming data release is a material event for DFTX and may influence sentiment in the psychiatric‑drug sector.
What to watch
Regulatory scrutiny of psychedelic compounds and potential scheduling changes could affect long‑term valuation regardless of trial data.
Background
Definium Therapeutics (NASDAQ:DFTX) is a late‑stage biopharma focused on psychedelic‑derived treatments for psychiatric disorders. The Panorama study is its second Phase 3 trial for DT120 in generalized anxiety disorder.
Ticker impact
Definium Therapeutics will host a webcast on Sep 14 to present topline Phase 3 Panorama study results for its GAD drug DT120.
Potential +/-10% swing on the day of the webcast depending on trial outcome.
Phase 3 data are material for a late‑stage biotech; market reaction is typically strong but direction is unknown until results are disclosed.
Market effects
GAD and broader psychiatric‑drug sector may see heightened volatility as investors gauge psychedelic‑based therapies.
US biotech market could experience short‑term trading activity around the release.
Limited to investors in biotech; no broader macro impact.
Counterpoint
If the market has already priced in a positive outcome, a neutral or negative readout could trigger a sharp correction.
Key entities
- companyDefinium Therapeutics, Inc.
Late‑stage biopharma developing psychedelic‑based therapies, ticker DFTX.
- drugDT120 (lysergide) ODT
Investigational oral disintegrating tablet for generalized anxiety disorder.
